Dapagliflozin Tablets
- Manufacturer
- Zydus Lifesciences Limited
- Effective date
- 2026-04-06
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 6
- Source
- full-release
- Hydrated at
- 2026-05-31 22:14:11
Label at a glance#
Label contents#
Full prescribing information#
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1488569 | dapagliflozin 10 MG Oral Tablet | PSN | 6 |
| 1488574 | dapagliflozin 5 MG Oral Tablet | PSN | 6 |
| 1488569 | dapagliflozin 10 MG Oral Tablet | SCD | 6 |
| 1488574 | dapagliflozin 5 MG Oral Tablet | SCD | 6 |
| 1488569 | dapagliflozin 10 MG Oral Tablet | SY | 6 |
| 1488574 | dapagliflozin 5 MG Oral Tablet | SY | 6 |
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| DAPAGLIFLOZIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c30aab5e-c89f-4b59-83b1-99a940b63351 | Product name | 1 | 20200925 |
| 1dc427fa-8c3b-4309-981e-ea1ff01326e5 | Product name | 1 | 20190731 |
| 85b4e38c-4488-4e48-919e-244e107d9bd9 | Product name | 2 | 20190731 |
| 5ec207a9-fa56-4ff7-8fae-9a7d9a6bf52c | Product name | 2 | 20170824 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70771-1714-3 | Dapagliflozin | 30 in 1 BOTTLE | TABLET | 30 | 6 | |
| 70771-1714-9 | Dapagliflozin | 90 in 1 BOTTLE | TABLET | 90 | 6 | |
| 70771-1715-3 | Dapagliflozin | 30 in 1 BOTTLE | TABLET | 30 | 6 | |
| 70771-1715-9 | Dapagliflozin | 90 in 1 BOTTLE | TABLET | 90 | 6 |
Products#
Every source-derived product name is available through these pages.
- Dapagliflozin
- ANHYDROUS LACTOSE
- CROSPOVIDONE
- HYPROMELLOSE 2910 (3 MPA.S)
- MICROCRYSTALLINE CELLULOSE
- POLOXAMER 407
- POLYETHYLENE GLYCOL 6000
- SILICON DIOXIDE
- SODIUM STEARYL FUMARATE
- TALC
- TITANIUM DIOXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 70771-1714 | 70771-1714-3, 70771-1714-9 |
| 70771-1715 | 70771-1715-3, 70771-1715-9 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211582-001 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | |
| A211582-002 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A211582-001 | AB |
| A211582-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2022-02-22 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2022-02-22 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2022-02-22 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2022-02-22 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2022-02-22 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2022-02-22 | 4b0b4de00fa7… | |
| 2024-02-18 07:12 UTC | 2024-02 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | 1c564ffb4f44… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | ea1830bbd6c7… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | a72a2bbeb626… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | 9b2671bbb829… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | a67488948f0b… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | 3f0d92c62455… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | 053a50430f4f… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | 3bdfa0b2c4d7… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | 3a93d1ddd44b… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | f41ea6bd6efb… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | 2022-02-22 | e64feba35796… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | 2022-02-22 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2022-02-22 | cb3db0bc1861… | |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2022-02-22 | cb3db0bc1861… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211582-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211582-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A211582-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211582-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A211582-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211582-002 | AB | 1 | caaa826d4ba7… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A211582-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A211582-002 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A211582-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A211582-002 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A211582-001 | AB | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | A211582-002 | AB | 1 | 4b0b4de00fa7… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A211582-001 | AB | 1 | cb3db0bc1861… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A211582-002 | AB | 1 | cb3db0bc1861… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211582-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211582-002 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dapagliflozin | DAPAGLIFLOZIN | Zydus Lifesciences Limited | db668c5c-2d49-41c8-8ffd-c2b2652b621a | 2026-04-06 | 70771-1715-3 70771-1715-9 70771-1714-3 70771-1714-9 70771-1715 70771-1714 70771171509 70771171409 70771171403 70771171503 e0ce1921-cd6e-4663-acd0-ae34bd8222fa db668c5c-2d49-41c8-8ffd-c2b2652b621a |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.

